Exegenesis Bio

Exegenesis Bio is a private, pre-revenue biotech firm developing gene therapies for rare diseases with an emphasis on novel delivery platforms. The company maintains a dual operational footprint in the United States and China, aiming to leverage research and development capabilities across both regions. While specific pipeline details are not publicly disclosed on its minimal website, its stated focus is on creating treatments for underserved rare genetic conditions. The company appears to be in an early, likely preclinical, development stage as it builds its technology and programs.

Novel delivery technologies for gene and cell therapies, likely focused on next-generation viral vectors (e.g., engineered AAV capsids) or non-viral systems to improve targeting, safety, and manufacturability.

Exegenesis operates in a highly competitive space competing against large biopharma (e.g., Novartis, Roche, Pfizer) and numerous well-funded biotechs (e.g., Sarepta, BioMarin, uniQure) also advancing gene therapies. It also competes with specialized platform companies (e.g., Dyno Therapeutics, 4D Molecular Therapeutics) focused on next-generation AAV capsid engineering.